Plunkett Research Online: Onxeo

ONXEO (OXNXF:GREY) Company Profile, Corporate Revenues, Growth, Market Size, Analysis, Business Forecasts, Market Share, Metrics, SWOT

Onxeo SA is engaged in the development of drugs for the treatment of orphan diseases in particular in oncology. Its pipeline products include AsiDNA 1V, AsiDNA+chemo/radio, AsiDNA+Belinostat/HDACi and others......



Onxeo
Ticker: OXNXF
Exchange: GREY
Parent Company:
Year Established:
Employees:
Fiscal Year Ends in

Phone: 33 145587600
Fax: 33 145580881
Address: 49 Boulevard du General
Martial Valin
Paris, 75015 France

Types Of Business
Industry Ranks

Industry NAICS code:


Ranks not available
ContactsDescription

Onxeo SA is engaged in the development of drugs for the treatment of orphan diseases in particular in oncology. Its pipeline products include AsiDNA 1V, AsiDNA+chemo/radio, AsiDNA+Belinostat/HDACi and others......See More See More

Auditor: Grant Thornton
Legal Advisor:
$USD, In whole numbers,
except marked * or %
201720162015201420132012
Financials
    Revenue
    Cost of Revenue
    Gross Margin %
    R&D Expense
    Operating Income
    Operating Margin %
    SGA Expense
    Net Income
    Earnings Per Share
    Dividends
    Book Value Per Share
    Operating Cash Flow
    Capital Expenditure
    Free Cash Flow
Profitability
    EBITDA
    Return on Assets %
    Return on Equity %
    Net Margin %
    Assets Turnover
    Financial Leverage
Brands, Divisions and AffiliatesTop Salaries
Other ThoughtsCorporate Culture

Apparent Female Officers or Directors: